Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma of the Lung
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
Primary objective: To investigate the prevalence of MET and TP53 mutations, as well as HER2 and MET amplification, in lung and head and neck tumours, through prospective collection of tumour specimens in newly recruited patients. Secondary objectives: To distinguish the presence of somatic/germline ...
Primary objective: To investigate the prevalence of MET and TP53 mutations, as well as HER2 and MET amplification, in lung and head and neck tumours, through prospective collection of tumour specimens in newly recruited patients. Secondary objectives: To distinguish the presence of somatic/germline MET and TP53 mutation in lung and head and neck tumours. To detect for amplifications of MET and/or HER2 genes in SCC samples. To investigate the association and interaction of cMet and HER2 in SCC tumours. To establish a prospective documation of clinical, histopathological, treatment and follow-up (clinic pathological) data of newly recruited patients.
Tracking Information
- NCT #
- NCT03938012
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Boon Cher Goh Study Principal Investigator
Get Well Soon